Human Albumin Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Human Albumin market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the increasing demand for biopharmaceuticals, a rise in clinical trials, growing health concerns, higher healthcare expenditures, and an expanding need for human serum albumin-based therapies.

The anticipated growth during the forecast period can be attributed to factors such as the rising incidence of chronic diseases, advancements in healthcare, an increasing number of surgeries, an expanding elderly population, growing government initiatives, and heightened awareness of human albumin and plasma. Key trends in the forecast period include facility expansion, drug approvals by authorities, strategic collaborations, the rise of personalized medicine, and technological advancements.

The increasing prevalence of chronic disorders is expected to drive the growth of the human albumin market. Chronic disorders, or chronic diseases, are long-term conditions requiring ongoing medical management. Factors such as aging populations, sedentary lifestyles, unhealthy dietary habits, and elevated stress levels are key contributors to the rising incidence of these conditions. Human albumin is used in managing chronic kidney disease to address hypoalbuminemia, maintain oncotic pressure, and improve fluid balance, thereby reducing complications. For instance, in June 2023, Kidney Research UK, a UK-based charity, reported that approximately 7.2 million individuals in the UK, representing over 10% of the population, are affected by chronic kidney disease. Of these, 3.25 million are in severe stages, while an additional 3.9 million are in the early stages, often undiagnosed and asymptomatic. By 2033, the number of individuals with chronic kidney disease is projected to reach 7.61 million. Thus, the rising prevalence of chronic disorders is driving the human albumin market.

A key trend in the human albumin market is the focus on securing drug approvals from regulatory authorities to gain a competitive advantage. Drug approvals ensure that medications meet safety, efficacy, and quality standards, boosting confidence among healthcare providers and patients. Additionally, approval allows products to be legally marketed and sold, increasing their reach and market potential. For instance, in June 2023, Kedrion Biopharma Inc., an Italy-based biopharmaceutical company, announced the approval of Bio Products Laboratory (BPL)'s human albumin product by China's National Institutes for Food and Drug Control (NIFDC). This milestone marks the first BPL product approved for the Chinese market, facilitating regular shipments to China, the largest consumer of human albumin, which accounted for 627 tons of demand out of a global total of 1,368 tons in 2021.

In April 2022, Grifols SA, a Spain-based pharmaceutical company, acquired Biotest AG for $1.15 billion. This acquisition significantly enhances Grifols' strategic position in the healthcare market, particularly in plasma-derived therapies. Biotest AG, a Germany-based pharmaceutical company, specializes in manufacturing immunoglobulins, clotting factors, and human albumins.

Major companies operating in the human albumin market are Takeda Biopharmaceuticals Private Ltd., Merck KGaA, Baxter International Inc., CSL Behring, Grifols SA, Octapharma AG, Sanquin Plasma Products BV, Taibang Biologic Group, Bovogen Biologicals Pty Ltd., and Akron Biotech.

North America was the largest region in the human albumin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human albumin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the human albumin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Human albumin is a naturally occurring protein in plasma that plays a key role in maintaining oncotic pressure and transporting hormones, enzymes, drugs, and other substances throughout the bloodstream. Medically, human albumin is administered intravenously as a solution derived from pooled human plasma to treat conditions such as hypovolemia, hypoalbuminemia, burns, and acute respiratory distress syndrome (ARDS). It is also used in surgeries, including liver transplants and dialysis, to restore blood volume and stabilize circulation. Its ability to bind and transport molecules makes it an essential component in treatments for fluid replacement and shock management.

The primary types of human albumin products include human serum albumin, recombinant albumin, and bovine serum albumin. Human serum albumin is a protein found in human blood plasma that is crucial for maintaining osmotic pressure and transporting molecules such as hormones and drugs. Human albumin is used in the production of human serum albumin products to ensure compatibility and support physiological functions in medical treatments. It is used in the treatment of hypovolemia, hypoalbuminemia, burns, shock, liver diseases, neonatal conditions, and in surgical and critical care. Its applications include therapeutics, drug formulation and vaccines, media components, and other uses. It is employed by a range of end users, including hospitals, clinics, the pharmaceutical and biotechnology industries, and research institutes.

The human albumin market research report is one of a series of new reports that provides human albumin market statistics, including human albumin industry global market size, regional shares, competitors with a human albumin market share, detailed human albumin market segments, market trends and opportunities, and any further data you may need to thrive in the human albumin industry. This human albumin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human albumin market consists of sales of albumin solutions, albumin for plasma exchange, albumin for cell culture, and albumin for surgical applications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.